Cardiology · AnticoagulationTrial Updateclinicalmid-term

Study on VTE Prevention in Hip and Knee Arthroplasty Comparing Aspirin and Rivaroxaban

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/28/2026, 12:30:43 PM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial comparing aspirin and rivaroxaban for VTE prevention in hip and knee arthroplasty is significant as it may reshape treatment protocols and influence market dynamics for anticoagulants. Pharma companies must stay informed on the trial outcomes to adjust their strategies accordingly. Regulatory context from MHRA (Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension) supports the near-term read. Assessment grounded in 5 ranked evidence items (2 high-relevance).

Strategic Assessment

Pharma outcomes to adapt strategies for anticoagulant offerings in orthopedic surgery. The strongest clinical anchor is Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov), sponsor/company relevance (novartis). In cardiology, 3 regulatory and 1 competitive items passed relevance filtering for clinical guidelines.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts (Pfizer) — sponsor/company relevance (pfizer). Results may influence treatment protocols and market positioning for anticoagulants in surgical settings, particularly for rivaroxaban.

Regulatory Outlook

Regulatory risk is concentrated around Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension (MHRA). Sub-indication match (cardiology); Regulatory pathway relevance (indication). Relevant agencies in corpus: MHRA, FDA. The results may lead to changes in clinical guidelines and potentially impact the regulatory landscape for anticoagulant approvals and indications.

Key Risks

Elevated medium regulatory exposure for clinical guidelines could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on clinical guidelines through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

Depending on the trial results, there could be shifts in market share for anticoagulants, particularly rivaroxaban, affecting revenue streams for companies involved in this therapeutic area.
Upside for clinical guidelines may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Pharma outcomes to adapt strategies for anticoagulant offerings in orthopedic surgery.

What Would Change This Assessment

This becomes more urgent if Key milestones include trial results publication and subsequent changes in clinical guidelines for VTE prevention.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
MHRAhigh relevance
Sub-indication match (cardiology); Regulatory pathway relevance (indication)
FDA document
View source
Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RIVAROXABAN (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RIVAROXABAN (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE AND ASPIRIN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE AND ASPIRIN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in Horses
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Clinical Practice of Hydromorphone in Multimodal Analgesia for Enhanced Recovery After Surgery (ERAS) in Knee Arthroplasty
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparing Effects of Custom Foot Orthotic Intervention to Foot-Core Training Protocol on Lower Extremity Kinematics in Runners With Pes Planus
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Nurse-Led Self-Compassion and Kindness Program on Compassion and Healthy Peer Relationships Among Adolescents: A Randomized Controlled Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Long-term Aseptic Revision & Advanced Hip Arthroplasty Database
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
ICU CONNECT: Study Comparing EMG in Healthy Volunteers and ICU Patients.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ethnopharmacological potential and mechanistic study of Platycodon grandiflorum stems and leaves and Lonicera japonica stems and leaves against acute lung injury.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Integrated exposure-based therapy for co-occurring post-traumatic stress and substance use among young people: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

clinical guidelines

Commercial impact

medium

Depending on the trial results, there could be shifts in market share for anticoagulants, particularly rivaroxaban, affecting revenue streams for companies involved in this therapeutic area.

Regulatory impact